Last reviewed · How we verify
Placebo matching DBPR108; Sitagliptin; DBPR108
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose.
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo matching DBPR108; Sitagliptin; DBPR108 |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Sitagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to glucose-dependent stimulation of pancreatic beta cells to increase insulin secretion and suppression of glucagon secretion, resulting in improved glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Hypoglycemia
- Upper respiratory tract infection
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: